Evaluation of the efficacy and safety of trimonthly intravitreal injection of aflibercept for retinal vein occlusion

Evaluation of the efficacy and safety of trimonthly intravitreal injection of aflibercept for retinal vein occlusion - Trimonthly intravitreal injection of aflibercept for retinal vein occlusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020403

Enrollment

Registered

2015-12-30

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

Duration:12 months Quantity: aflibercept 2.0mg/0.05mL Trimonthly injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science Hospital with retinal vein occlusion Patients underwent a full ocular examination, including fluorescein angiography

Exclusion criteria

Exclusion criteria: severe renal disease unstable angina malignant arrhythmia history of brain infarction history of cerebral hemorrhage severe hypertension

Design outcomes

Primary

Measure	Time frame
change in best-corrected visual acuity (BCVA) from baseline to 6 and 12 months	—

Secondary

Measure	Time frame
rate of adverse events change in central retinal thickness from baseline to 6 and 12 months	—

Countries

Japan

Contacts

Public ContactYoshitsugu Saishin

Shiga University of Medical Science Department of Ophthalmology

saishin@belle.shiga-med.ac.jp077-548-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026